|
May 6
|
Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)
|
|
May 4
|
Amneal Pharmaceuticals Inc (AMRX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
|
|
May 3
|
Amneal Reports First Quarter 2024 Financial Results
|
|
Feb 27
|
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
|
|
Jan 25
|
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
|
|
Jan 10
|
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
|
|
Dec 21
|
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 15
|
Amneal Announces Move to Nasdaq
|
|
Dec 7
|
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
|
|
Dec 1
|
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
|
|
Nov 27
|
Should You Be Excited About Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 20% Return On Equity?
|
|
Nov 10
|
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
|
|
Nov 8
|
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
|
|
Nov 7
|
Amneal Pharmaceuticals Inc (AMRX) Reports 14% Increase in Q3 2023 Net Revenue
|
|
Nov 7
|
Amneal Reports Third Quarter 2023 Financial Results
|
|
Nov 6
|
Amneal Pharmaceuticals (NYSE:AMRX) delivers shareholders decent 83% return over 1 year, surging 11% in the last week alone
|
|
Nov 3
|
JPMorgan Overhauls Loan for Amneal Pharmaceuticals After Investor Backlash
|
|
Nov 3
|
Amneal to Participate at Upcoming Investor Conferences
|
|
Nov 1
|
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Should You Buy?
|